生物制剂开发商Coya Therapeutics宣布1110万美元私募融资-动脉网

Coya Therapeutics Announces $11.1 Million Private Placement IR Contact Email Alerts

Coya Therapeutics 等信源发布 2026-01-30 21:20



可切换为仅中文







Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment

Coya当前战略合作伙伴的子公司Dr. Reddy’s Laboratories, Inc.进行了1000万美元的投资。

Greenlight Capital, Coya’s largest institutional shareholder, is the only other investor participating in the offering

绿光资本是科亚最大的机构股东，也是参与此次发行的唯一其他投资者。

HOUSTON--(BUSINESS WIRE)--

休斯顿--（商业资讯）--

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share.

Coya Therapeutics, Inc.（纳斯达克股票代码：COYA）（“Coya”或“公司”），一家专注于开发增强神经退行性疾病患者调节性T细胞（Treg）功能的生物制剂的临床阶段生物技术公司，今天宣布已达成一份最终证券购买协议，以每股4.40美元的价格在私募中出售总计2,522,727股普通股。

The offering is expected to close on or about January 30, 2026, subject to the satisfaction of customary closing conditions. The investors in the offering are Dr. Reddy’s Laboratories, Inc. ($10 million) and Greenlight Capital ($1.1 million), an existing institutional stockholder of the Company..

预计此次发行将在2026年1月30日或左右完成，但需满足惯例的交割条件。本次发行的投资者包括Dr. Reddy's Laboratories, Inc.（1000万美元）和公司现有机构股东Greenlight Capital（110万美元）。

The gross proceeds to the Company from the private placement are expected to be approximately $11.1 million, before deducting offering expenses payable by the Company.

公司从此次私募中获得的毛收入预计约为 1,110 万美元，尚未扣除公司应支付的发行费用。

No broker, placement agent or investment banker was engaged in the transaction. The Company intends to use the net proceeds to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support the commercial readiness of COYA 302.

未涉及任何经纪人、配售代理或投资银行家。公司打算利用净收益加速低剂量IL-2的技术转移和规模化生产活动，以支持COYA 302的商业准备。

The offer and sale of the securities described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and have not been registered under the Act, or applicable state securities laws. Accordingly, the securities issued in the private placement may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws..

上述证券的要约和出售是根据修订后的《1933年证券法》（“该法案”）第4(a)(2)条进行的私募发行，且尚未根据该法案或适用的州证券法进行注册。因此，在美国境内，除非依据有效的注册声明或适用的该法案及此类州证券法的注册要求豁免，否则不得要约或出售此次私募发行中发行的证券。

The Company has agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) covering the resale of the securities to be issued in the offering no later than 45 days following the date of the closing of the offering, and to have such registration statement declared effective by the SEC as promptly as possible but in any event no later than 75 days following the date of the closing of the offering, subject to extension under the terms of the definitive securities purchase agreement..

公司已同意在发行结束之日起不迟于45天内向证券交易委员会（“SEC”）提交一份涵盖本次发行中将要发售的证券的注册声明，并尽快使该注册声明被SEC宣布生效，但无论如何不得晚于发行结束之日起75天内，且受制于最终证券购买协议条款下的延期。

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction..

本新闻稿不构成出售或招揽购买本文所述任何证券的要约，且在任何州或其他司法管辖区，不得在根据该州或其他司法管辖区的证券法进行注册或资格认证之前，进行此类证券的出售、要约或招揽，因为这将是违法的。

About COYA 302

关于COYA 302

COYA 302 is an investigational and proprietary biologic combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages. COYA 302 comprises proprietary low dose interleukin-2 (LD IL-2) and CTLA-4 Ig and is being developed for subcutaneous administration for the treatment of patients with ALS and other neurodegenerative diseases.

COYA 302 是一种研究性、专有的生物组合疗法，具有双重免疫调节作用机制，旨在增强调节性 T 细胞 (Tregs) 的抗炎功能，并抑制活化的单核细胞和巨噬细胞产生的炎症。COYA 302 包含专利的低剂量白介素-2（LD IL-2）和 CTLA-4 Ig，正在开发用于皮下注射，以治疗 ALS 和其他神经退行性疾病患者。

These mechanisms may have additive or synergistic effects..

这些机制可能具有相加或协同效应。

Coya is currently conducting the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (

Coya目前正在开展ALSTARS试验，这是一项二期、随机、多中心、双盲、安慰剂对照的研究，旨在评估COYA 302治疗ALS的疗效和安全性（

ClinicalTrials.gov

临床试验.gov

Identifier: NCT 07161999).

标识符：NCT 07161999）。

COYA 302 is an investigational product not yet approved by the FDA or any other regulatory agency.

COYA 302 是一种尚未获得 FDA 或任何其他监管机构批准的在研产品。

About Coya Therapeutics, Inc.

关于Coya治疗公司

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells ('Tregs') to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases.

总部位于德克萨斯州休斯顿的Coya Therapeutics, Inc.（纳斯达克代码：COYA）是一家临床阶段的生物技术公司，致力于开发基于调节性T细胞（“Tregs”）生物学特性及其潜在治疗优势的专有疗法，以针对系统性炎症和神经炎症。Tregs功能障碍是包括神经退行性疾病、代谢性疾病和自身免疫疾病在内的多种病症的基础。

This cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system..

这种细胞功能障碍可能导致持续的炎症和氧化应激，导致免疫系统稳态的缺失。

Coya’s investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coya’s therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Coya的研发产品候选管线利用多种治疗模式，旨在恢复Treg的抗炎和免疫调节功能。Coya的治疗平台包括增强Treg的生物制剂、Treg衍生的外泌体以及自体Treg细胞疗法。

For more information about Coya, please visit

有关 Coya 的更多信息，请访问

https://coyatherapeutics.com/

Forward Looking Statements

前瞻性声明

This press release contains 'forward-looking' statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this press release, including information concerning our current and future financial performance, business plans and objectives, current and future clinical and preclinical development activities, timing and success of our ongoing and planned clinical trials and related data, the timing of announcements, updates and results of our clinical trials and related data, our ability to obtain and maintain regulatory approval, the potential therapeutic benefits and economic value of our product candidates, competitive position, industry environment and potential market opportunities.

本新闻稿包含基于管理层信念、假设以及管理层目前可获得信息的“前瞻性”陈述。前瞻性陈述包括本新闻稿中除历史事实陈述之外的所有陈述，包括有关我们当前和未来的财务表现、业务计划与目标、当前和未来的临床及临床前开发活动、正在进行和计划中的临床试验及其相关数据的时间安排与成功与否、我们临床试验及相关数据的公告、更新和结果的时间、我们获得并维持监管批准的能力、我们的产品候选者的潜在治疗益处与经济价值、竞争地位、行业环境以及潜在市场机会的信息。

The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' and similar expressions are intended to identify forward-looking statements..

“相信”、“可能”、“将”、“估计”、“继续”、“预期”、“打算”、“预计”等词语及类似表达旨在识别前瞻性陈述。

Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those related to market conditions; the satisfaction of customary closing conditions related to the private placement and other uncertainties related to the private placement; the anticipated use of proceeds from the private placement; risks associated with the success, cost and timing of our product candidate development activities and ongoing and planned clinical trials; our plans to develop and commercialize targeted therapeutics; the progress and timing of patient enrollment and dosing in our preclinical or clinical trials; the ability of our product candidates to achieve applicable endpoints in the clinical trials; our exploratory clinical signals may not be predictive of outcomes in larger, randomized controlled trials; the safety profile of our product candidates; the potential for data from our clinical trials to support a marketing application, as well as the timing of these events; our ability to obtain funding for our operations; development and commercialization of our product candidates; the timing of and our ability to obtain and maintain regulatory approvals; anticipated interactions with the FDA under Fast Track designation; the rate and degree of market acceptance and clinical utility of our product candidates; the size and growth potential of the markets for our product candidates, and our ability to serve those markets; our commercialization, marketing and manufacturing capabilities and strategy; future agreements with third parties in connection with the commercialization of our product candidates; our expectations regarding our ability to obtain and maintain intellectual property protection; our dependence on.

前瞻性声明受到已知和未知风险、不确定性、假设及其他因素的影响，包括但不限于与市场状况相关的因素；与私募发行相关的惯例交割条件的满足及其他与私募发行相关的不确定性；私募发行所得款项的预期用途；与我们的候选产品研发活动及正在进行和计划中的临床试验的成功、成本和时间安排相关的风险；我们开发和商业化靶向治疗的计划；我们在临床前或临床试验中患者入组和给药的进展和时间安排；我们的候选产品在临床试验中达到适用终点的能力；我们的探索性临床信号可能无法预测更大规模随机对照试验的结果；我们的候选产品的安全性特征；我们的临床试验数据可能支持上市申请的潜力以及这些事件的时间安排；我们为运营获取资金的能力；我们的候选产品的开发和商业化；我们获得和维持监管批准的时间和能力；在快速通道指定下与FDA的预期互动；我们的候选产品在市场上的接受度和临床实用性的速度和程度；我们的候选产品市场的规模和增长潜力，以及我们服务这些市场的能力；我们的商业化、营销和制造能力及策略；与第三方就我们候选产品的商业化达成的未来协议；我们对我们获取和维持知识产权保护能力的预期；我们的依赖性。

We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.

我们做出这些前瞻性陈述的主要依据是当前的预期和对未来事件及趋势的预测，我们认为这些事件和趋势可能会影响我们的财务状况、经营成果、业务战略、短期和长期业务运营及目标，以及财务需求。

Moreover, we operate in a very competitive and rapidly changing environment, and new risks may emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.

此外，我们处在一个竞争非常激烈且变化迅速的环境中，新的风险可能会不时出现。我们的管理层无法预测所有风险，也无法评估所有因素对我们业务的影响，或任何因素或因素组合可能导致实际结果与我们所做的任何前瞻性陈述中的内容存在重大差异的程度。

In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed herein may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Although our management believes that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances described in the forward-looking statements will be achieved or occur.

鉴于这些风险、不确定性和假设，本文讨论的前瞻性事件和情况可能不会发生，实际结果可能与前瞻性声明中预期或暗示的结果有重大不利差异。尽管我们的管理层认为前瞻性声明中反映的预期是合理的，但我们无法保证前瞻性声明中描述的未来结果、活动水平、绩效或事件和情况将会实现或发生。

We undertake no obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise..

我们不承担公开更新任何前瞻性陈述的义务，无论这些陈述是书面还是口头作出的，也不论其是否因新信息、未来发展或其他原因而作出。

Investor Contact

投资者联系人

David Snyder, CFO

大卫·斯奈德，首席财务官

david@coyatherapeutics.com

大卫@coyatherapeutics.com

astr partners

天体伙伴

Matthew Beck

马修·贝克

matthew.beck@astrpartners.com